Phase 3 VISION Trial Shows Promising Results in Advanced Prostate Cancer


The use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death among patients with advanced prostate cancer.

In a recent interview with Pharmacy Times, medical oncologist Michael Morris, MD, discussed the newest findings of the phase 3 VISION trial, which is investigating the use of 177Lu-PSMA-617 in patients with advanced prostate cancer. These new findings will be presented at the American Society of Clinical Oncology 2021 annual meeting.

The trial was conducted in patients with metastatic, advanced prostate cancer whose disease was no longer responding to multiple other interventions. The trial had 2 primary endpoints: overall survival and radiographic progression-free survival. Morris said the use of 177Lu-PSMA-617 resulted in a 60% reduction in radiographic progression or death.

Related Videos
car t cell therapy multiple myeloma/Image Credit: © Lusi_mila -
Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room - Image credit: pressmaster |
palliative and hospice care/ Image Credits: © David Pereiras -
cancer pain management | Image Credits: © Burlingham -
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic -
multiple myeloma clinical trial/Image Credits: © Studio Romantic -
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign |
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk -
pharmacy oncology, Image Credit: © Konstantin Yuganov -
© 2024 MJH Life Sciences

All rights reserved.